Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child
Article in Expert Review of Anticancer Therapy (April 2024)
The most recent citing publications are shown below. View all 150 publications that cite this research output on Dimensions.
Article in Expert Review of Anticancer Therapy (April 2024)
Article in Targeted Oncology (March 2024)
Article in Journal of Oncology Pharmacy Practice (February 2024)